text:
Support our growth
History of Parliament Trust
Journal of the House of Lords: volume 20: 1714-1717
Year published
486, 487, 488
Comment on this articleDouble click anywhere on the text to add an annotation in-line
Citation Show
another format:
'House of Lords Journal Volume 20: 4 June 1717', Journal of the House of Lords: volume 20: 1714-1717 (1767-1830), pp. 486-488. URL: http://www.british-history.ac.uk/report.aspx?compid=38662 Date accessed: 24 November 2014.
(Min 3 characters)
DIE Martis, 4 Junii.
Moor et al. versus Mattocks et al.
Nugent's Bill:
His Majesty's Consent to it.
Sale of Thynne's Estate, Bill.
D. of Montagu's Bill.
Davies's Bill.
L. Caher versus Nagle:
Hearing appointed.
Act for Papists to Register their Estates, Bill to explain.
Domini tam Spirituales quam Temporales præsentes
This Day being appointed, to hear Counsel, upon
the Petition and Appeal of Boyl Moor, Henry Edgworth
and Elizabeth his Wife, Thomas Burridge, and John
Cary, complaining of an Order made in the Court of
Chancery in Ireland, the Third of December 1715, in a
Cause wherein Thomas Mattocks, Henry Bridges, Richard
Healy, and Thomas Amory, were Plaintiffs, and the Appellants Defendants, so far as the said Order relates
to the Allowance of the Plaintiffs Exceptions to the
Master's Report, and the Disallowance of the Appellants Exceptions; and also of several other Orders of
the said Court; to which Appeal the said Thomas Mattocks, Henry Bridges and Thomas Amory, put in their
Counsel accordingly were called in, to be heard
in the said Cause.
And the Counsel for the Appellants proceeding:
The Respondents Counsel objected to the Generality of
the Appeal.
And the Counsel on both Sides being heard thereupon;
They withdrew.
And it was agreed, by the House, that the Hearing
of the said Cause should stand over to a further Day,
in regard to the Objection made by the Respondents
Counsel as to the Form and Manner of the said Appeal: And Ordered, That the Appellants Agents do,
within Three Days, give to the Respondents Agents
Notice, in Writing, of the particular Exceptions, and
Branches of Exceptions, they intend to insist and stand
upon; and that the Appellants do pay, or cause to be
paid, to the Respondents, the Sum of Twenty Pounds,
for their Costs of this Day's Attendance, in respect of
the Generality and Irregularity of the said Appeal.
Then the Counsel were called in again; and the Lord
Chancellor acquainted them therewith.
And being withdrawn;
Ordered, That the Hearing the said Cause be adjourned, to Saturday the Fifteenth Day of this Instant
June, at Eleven a Clock.
The House being moved, "That the Bill, intituled,
An Act to enable Susanna Catherina Nugent to sue for,
recover, and hold, the Portion of Fourteen Hundred
Pounds, provided for her out of her Father's Estate,
notwithstanding her Coverture, and the Outlawry of
her Husband Hyacinthus Nugent Esquire," be now
read the First Time.
The Earl of Sunderland signified to the House, "That
His Majesty, having been acquainted with what the
said Mrs. Nugent desires by the Bill, is willing the
same may be proceeded in; and that His Interest
may not interfere with any Redress she may obtain
Then the said Bill was read the First Time.
After reading, and considering, the Report of the
Judges, to whom the Petition of John Conyers Esquire
was referred; praying Leave to bring in a Bill, for the
Purposes in the Petition mentioned:
It is Ordered, That Leave be given to bring in a
Bill, according to the Prayer of the Petition, and pursuant to the Judges Report.
Hodie 1a
vice lecta est Billa, intituled, "An Act
for vesting an Estate at Corsham, in Wiltshire, in the
surviving Trustee and Executor of the last Will of
Henry Frederick Thynne Esquire deceased, and his
Heirs, to make Sale thereof, for the Execution of
the Trusts created by his Will."
Hodie 2a
vice lecta est Billa, intituled, "An Act for
the Sale of Part of the Duke of Montagu's Estate,
for the Intents and Purposes therein mentioned; and
for settling other Estates; in Lieu thereof, to the
same Uses."
Ordered, That the said Bill be committed to the
Consideration of the Lords following; videlicet,
Their Lordships, or any Five of them; to meet
on Wednesday the Nineteenth Day of this Instant June, at Ten a Clock in the Forenoon, in the
Prince's Lodgings near the House of Peers; and
to adjourn as they please.
The Lord Bishop of St. Asaph reported from the
Lords Committees, to whom the Bill, intituled, "An
Act for rectifying Defects in a Settlement made by
Robert Davies Esquire, deceased, of certain Estates
in the Counties of Denbigh and Flint, and effectually
securing the Payment of his Debts, and making Provision for the Younger Children of Robert Davies
his Son, and settling the said Estates subject thereto,"
was committed: "That they had considered the said
Bill, and found the Allegations thereof to be true;
that the Parties concerned had given their Consents;
and that the Committee had made some Amendments
to the Bill."
Which were read Twice, and agreed to.
Ordered, That the Bill, with the Amendments, be
The House being moved, "That a Day may be
appointed, for hearing the Cause wherein Thomas
Lord Baron of Caher in the Kingdom of Ireland is Appellant, and Catherine Nagle and others Respondents:
It is Ordered, That this House will hear the said
Cause, by Counsel, at the Bar, on Saturday the Sixth
Day of July next, at Eleven a Clock.
Ordered, That the Bill, intituled, "An Act for
explaining an Act passed the last Session of Parliament,
intituled, An Act to oblige Papists to register
their Names and Real Estates; and for enlarging the
"Time for such registering," which was appointed to
be read a Second Time To-morrow, be read a Second
Time on Thursday next; and the Lords to be summoned
then to attend.
Dominus Cancellarius declaravit præsens Parliamentum continuandum esse usque ad et in diem Jovis, sextum diem instantis Junii, hora undecima Aurora, Dominis sic decernentibus.
Double-click menu [ Cancel ]
- Contact us -
Privacy & Cookies - Terms of use - FAQ - About
Support us
Version 4.0 | November 2013
© 2014 University of London & History of Parliament Trust
Design - Crave Ltd


text:
This article describes the formula syntax and usage of the REPLACE and REPLACEB function (function: A prewritten formula that takes a value or values, performs an operation, and returns a value or values. Use functions to simplify and shorten formulas on a worksheet, especially those that perform lengthy or complex calculations.) in Microsoft Excel.
REPLACE replaces part of a text string, based on the number of characters you specify, with a different text string.
REPLACEB replaces part of a text string, based on the number of bytes you specify, with a different text string.
Important REPLACE is intended for use with languages that use the single-byte character set (SBCS), whereas REPLACEB is intended for use with languages that use the double-byte character set (DBCS). The default language setting on your computer affects the return value in the following way:
The languages that support DBCS include Japanese, Chinese (Simplified), Chinese (Traditional), and Korean.
REPLACE(old_text, start_num, num_chars, new_text)
REPLACEB(old_text, start_num, num_bytes, new_text)
The REPLACE and REPLACEB function syntax has the following arguments (argument: A value that provides information to an action, an event, a method, a property, a function, or a procedure.):
The example may be easier to understand if you copy it to a blank worksheet.
How do I copy an example?
Selecting an example from Help
After you copy the example to a blank worksheet, you can adapt it to suit your needs.
Example 2: REPLACEB (with your computer set to a default language that supports DBCS)
In the following example:
=REPLACEB(" ",4,4," ") equals " "
=REPLACE(" ",4,4," ") equals " "

subset: commoncrawl


text:
Authorities are trying to determine how a man was shot to death behind his Scottsboro home on Christmas.
Jackson County sheriff's officials told WAFF-TV that 53-year-old Michael Hart was putting grain in a feeder and checking on a game camera behind his home when he was killed.
The shooting happened on Jackson County Road 11 between Scottsboro and Woodville.
Hart's wife found him lying next to his four-wheeler and thought he'd had a heart attack. Doctors discovered that Hart had been shot once he got to the hospital.
Jackson County Sheriff Chuck Phillips said it's possible the shooting was a hunting accident, and authorities are trying to determine who might have been hunting in the area at the time.
Get breaking news from the Times Free Press on Twitter at www.twitter.com/timesfreepress or by visiting us on Facebook or Twitter at the right:


text:
William Pao, M.D., Ph.D.
Cornelius Abernathy Craig Professor of Medical & Surgical Oncology
Professor and Director of Hematology/Oncology
Professor of Cancer Biology and Pathology/Microbiology/Immunology
Director, Personalized Cancer Medicine
VICC Member
Medical Oncologist
- Appointments
Physicians: 1-877-936-8422
- Clinical Trials Information
- Clinical Trials: 1-800-811-8480
- Online Self-Referral Form
- Other Telephone NumbersHenry-Joyce Cancer Clinic
615-936-8422 or 1-877-936-8422
- FaxesHenry-Joyce Cancer Clinic Fax
Office Fax
- Addresses
Henry-Joyce Cancer Clinic
1301 Medical Center Drive, Suite 1710
Nashville, Tennessee 37232-7415
2220 Pierce Avenue
777 Preston Research Building
Nashville, TN 37232-6307
Dr. Pao is a physician-scientist with a special interest in thoracic oncology. Dr. Pao's research focuses on identification of genes involved in the pathogenesis of lung tumors and stratifying tumors into clinically relevant molecular subsets. Using information derived from these experiments, Dr.
Read more ....
Dr. Pao is a physician-scientist with a special interest in thoracic oncology. Dr. Pao's research focuses on identification of genes involved in the pathogenesis of lung tumors and stratifying tumors into clinically relevant molecular subsets. Using information derived from these experiments, Dr. Pao seeks to improve treatment for patients with non-small cell lung cancer. His research has yielded important insights into mechanisms of lung tumor sensitivity and resistance to inhibitors of the epidermal growth factor receptor.
Dr. Pao is the author of over 50 publications, is actively involved innumerous professional associations including the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO), and has served as a journal editor for PLoS Medicine, Cancer Research, and the Journal of Clinical Oncology.
- Ph.D. - Yale University, 1998
- M.D. - Yale University, 1990
- Fellowship - Memorial Sloan-Kettering Cancer Center, 2005
- Fellowship - Memorial Sloan-Kettering Cancer Center, 2004
- Internship - New York Presbyterian Hospital, 2000
- Residency - New York Presbyterian Hospital, 2000
Research Specialty
The Pao Laboratory aims to perform translational research in the area of solid tumor biology, using lung cancer as a paradigm. The overall goal is to develop molecularly-tailored treatments for patients with lung cancer.
Research Description
Lung cancer is the leading cause of cancer-related death in the U.S and worldwide. Most cases arise in former or current smokers, but about 10% of cases also occur in individuals who smoked less than 100 cigarettes in a lifetime ("never smokers"). Lung cancers are currently classified by histopathological techniques as either small-cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC). In North America, adenocarcinoma (a type of NSCLC) is the most frequent type of histological tumor, accounting for 40% of all cases of lung cancer.
New "targeted" epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) like gefitinib (Iressa) and erlotinib (Tarceva) have given us a window of opportunity to elucidate clinically relevant molecular subsets of lung adenocarcinomas. For example, clinical trials have shown that gefitinib has an overall response rate of 10% in American and European populations, and 28% in Japanese patients. Retrospective analyses suggested that gefitinib is most efficacious in "never smokers" with adenocarcinoma histology. Such findings can now be largely accounted for by research from our group and others showing the relatively high incidence of mutations in the gene encoding EGFR in these respective populations and the association of EGFR mutations with increased sensitivity to both gefitinib and erlotinib.
While EGFR mutations are common in tumors from never smokers, mutations in KRAS, which encodes a signaling molecule downstream of EGFR, more commonly occur in individuals with substantial cigarette use. Moreover, EGFR and KRAS mutations appear to be mutually exclusive, suggesting that EGFR and KRAS mutations within lung epithelia are equivalent in their tumorigenic effects. We found that mutations in KRAS are associated with primary resistance to these drugs. This suggests that pre-treatment mutational profiling of both EGFR and KRAS may help guide treatment decisions regarding the use of these agents.
Unfortunately, virtually all patients who initially respond to gefitinib and erlotinib eventually develop acquired resistance. We have shown that tumor cells from patients whose disease progresses after initial responses on therapy with these agents frequently harbor second-site mutations in EGFR. The predominant second mutation substitutes methionine for threonine at position 790 in EGFR, which is predicted to block binding of gefitinib and erlotinib to the ATP-binding pocket of the kinase. Interestingly, the T790M amino acid change is analogous to changes seen in other kinases targeted by a related kinase inhibitor, imatinib (Gleevec), in patients that develop acquired resistance to that drug. Using a genomic approach, we have also recently found that tumor samples from patients with acquired resistance to gefitinib or erlotinib harbor amplification of MET, which encodes another tyrosine kinase. MET amplification appears to occur independently of T790M mutations. Importantly, MET inhibitors are currently being developed in the clinic.
The Pao Laboratory is now focused on the following:
1) Defining further molecular subsets of lung cancers, based primarily upon mutational profiling of the oncogenome in tumor samples.
2) Elucidating other mechanisms of sensitivity and resistance to EGFR inhibitors in lung cancer. For example, we recently showed that in drug-sensitive EGFR mutant lung cancer cells, induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors. These data imply that the intrinsic pathway of caspase activation may influence sensitivity and/or resistance of EGFR mutant lung tumor cells to EGFR kinase inhibition.
3) Identifying ways to overcome resistance to gefitinib and erlotinib. We have generated mouse lung tumor models driven by EGFR T790M mutants and which are resistant to erlotinib. We are now using these models to uncover agents and strategies that overcome acquired resistance to the T790M amino acid change.
Clinical Research Description
The identification of genetic abnormalities that initiate and sustain cancers has paved the way to a new era of personalized anti-cancer therapies which are more effective than current approaches with fewer side effects. We aim to shape the practice of cancer medicine, envisioning a day when anti-cancer treatment will be assigned according to the genetic makeup of patients' tumors rather than on an empiric basis.
- Ohashi, K, Sequist, LV, Arcila, ME, Lovly, CM, Chen, X, Rudin, CM, Moran, T, Camidge, DR, Vnencak-Jones, CL, Berry, L, Pan, Y, Sasaki, H, Engelman, JA, Garon, EB, Dubinett, SM, Franklin, WA, Riely, GJ, Sos, ML, Kris, MG, Dias-Santagata, D, Ladanyi, M, Bunn, PA, Pao, W Characteristics of Lung Cancers Harboring NRAS Mutations. Clin Cancer Res, 19(9), 2584-2591, 2013.
- Abramson, RG, Abramson, VG, Chan, E, Horn, L, Keedy, VL, Pao, W, Sosman, JA Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. AJR Am J Roentgenol, 200(3), 475-83, 2013.
- Yeh, P, Chen, H, Andrews, J, Naser, R, Pao, W, Horn, L DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. Clin Cancer Res, 19(7), 1894-901, 2013.
- Brewer, MR, Pao, W Maximizing the benefits of off-target kinase inhibitor activity. Cancer Discov, 3(2), 138-40, 2013.
- Jia, P, Jin, H, Meador, CB, Xia, J, Ohashi, K, Liu, L, Pirazzoli, V, Dahlman, KB, Politi, K, Michor, F, Zhao, Z, Pao, W Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Res, 2013.
- Dahlman, KB, Xia, J, Hutchinson, K, Ng, C, Hucks, D, Jia, P, Atefi, M, Su, Z, Branch, S, Lyle, P, Hicks, DJ, Bozon, V, Glaspy, JA, Rosen, N, Solit, DB, Netterville, JL, Vnencak-Jones, CL, Sosman, JA, Ribas, A, Zhao, Z, Pao, W BRAF L597 mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov, 2012.
- Jia, P, Li, F, Xia, J, Chen, H, Ji, H, Pao, W, Zhao, Z Consensus rules in variant detection from next-generation sequencing data. PLoS One, 7(6), e38470, 2012.
- Yatabe, Y, Pao, W, Jett, JR Encouragement to Submit Data of Clinical Response to EGFR-TKIs in Patients With Uncommon EGFR Mutations. J Thorac Oncol, 7(5), 775-6, 2012.
- Lovly, CM, Pao, W Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Sci Transl Med, 4(120), 120ps2, 2012.
- Takezawa, K, Pirazzoli, V, Arcila, ME, Nebhan, CA, Song, X, de Stanchina, E, Ohashi, K, Janjigian, YY, Spitzler, PJ, Melnick, MA, Riely, GJ, Kris, MG, Miller, VA, Ladanyi, M, Politi, K, Pao, W HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov, 2(10), 922-33, 2012.
- Ohashi, K, Sequist, LV, Arcila, ME, Moran, T, Chmielecki, J, Lin, YL, Pan, Y, Wang, L, de Stanchina, E, Shien, K, Aoe, K, Toyooka, S, Kiura, K, Fernandez-Cuesta, L, Fidias, P, Yang, JC, Miller, VA, Riely, GJ, Kris, MG, Engelman, JA, Vnencak-Jones, CL, Dias-Santagata, D, Ladanyi, M, Pao, W Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A, 109(31), E2127-33, 2012.
- Xia, J, Wang, Q, Jia, P, Wang, B, Pao, W, Zhao, Z NGS catalog: A database of next generation sequencing studies in humans. Hum Mutat, 33(6), E2341-55, 2012.
- Pao, W New approaches to targeted therapy in lung cancer. Proc Am Thorac Soc, 9(2), 72-3, 2012.
- Lovly, CM, Dahlman, KB, Fohn, LE, Su, Z, Dias-Santagata, D, Hicks, DJ, Hucks, D, Berry, E, Terry, C, Duke, M, Su, Y, Sobolik-Delmaire, T, Richmond, A, Kelley, MC, Vnencak-Jones, CL, Iafrate, AJ, Sosman, J, Pao, W Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One, 7(4), e35309, 2012.
- Levy, MA, Lovly, CM, Pao, W Translating genomic information into clinical medicine: lung cancer as a paradigm. Genome Res, 22(11), 2101-8, 2012.
- Li, J, Su, Z, Ma, ZQ, Slebos, RJ, Halvey, P, Tabb, DL, Liebler, DC, Pao, W, Zhang, B A bioinformatics workflow for variant Peptide detection in shotgun proteomics. Mol Cell Proteomics, 10(5), M110.006536, 2011.
- Ohashi, K, Pao, W A new target for therapy in squamous cell carcinoma of the lung. Cancer Discov, 1(1), 23-4, 2011.
- Su, Z, Dias-Santagata, D, Duke, M, Hutchinson, K, Lin, YL, Borger, DR, Chung, CH, Massion, PP, Vnencak-Jones, CL, Iafrate, AJ, Pao, W A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn, 13(1), 74-84, 2011.
- Oxnard, GR, Arcila, ME, Sima, CS, Riely, GJ, Chmielecki, J, Kris, MG, Pao, W, Ladanyi, M, Miller, VA Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res, 17(6), 1616-22, 2011.
- Pao, W, Iafrate, AJ, Su, Z Genetically informed lung cancer medicine. J Pathol, 223(2), 230-40, 2011.
- Janjigian, YY, Park, BJ, Zakowski, MF, Ladanyi, M, Pao, W, D''Angelo, SP, Kris, MG, Shen, R, Zheng, J, Azzoli, CG Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J Thorac Oncol, 6(3), 569-75, 2011.
- Lovly, CM, Heuckmann, JM, de Stanchina, E, Chen, H, Thomas, RK, Liang, C, Pao, W Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res, 2011.
- Rizvi, NA, Rusch, V, Pao, W, Chaft, JE, Ladanyi, M, Miller, VA, Krug, LM, Azzoli, CG, Bains, M, Downey, R, Flores, R, Park, B, Singh, B, Zakowski, M, Heelan, RT, Shen, R, Kris, MG Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR Gene. Clin Cancer Res, 17(10), 3500-6, 2011.
- Pao, W, Girard, N New driver mutations in non-small-cell lung cancer. Lancet Oncol, 12(2), 175-80, 2011.
- Janjigian, YY, Azzoli, CG, Krug, LM, Pereira, LK, Rizvi, NA, Pietanza, MC, Kris, MG, Ginsberg, MS, Pao, W, Miller, VA, Riely, GJ Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin Cancer Res, 17(8), 2521-7, 2011.
- Johnson, ML, Riely, GJ, Rizvi, NA, Azzoli, CG, Kris, MG, Sima, CS, Ginsberg, MS, Pao, W, Miller, VA Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib. J Thorac Oncol, 6(6), 1128-31, 2011.
- Arcila, ME, Oxnard, GR, Nafa, K, Riely, GJ, Solomon, SB, Zakowski, MF, Kris, MG, Pao, W, Miller, VA, Ladanyi, M Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res, 17(5), 1169-80, 2011.
- Sengsayadeth, S, Montgomery, J, Pao, W T4 or MI. J Thorac Oncol, 6(3), 632, 2011.
- Garrett, JT, Olivares, MG, Rinehart, C, Granja-Ingram, ND, Sánchez, V, Chakrabarty, A, Dave, B, Cook, RS, Pao, W, McKinely, E, Manning, HC, Chang, J, Arteaga, CL Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A, 108(12), 5021-6, 2011.
- Zhao, B, Oxnard, GR, Moskowitz, CS, Kris, MG, Pao, W, Guo, P, Rusch, VM, Ladanyi, M, Rizvi, NA, Schwartz, LH A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res, 16(18), 4647-53, 2010.
- Girard, N, Lou, E, Azzoli, CG, Reddy, R, Robson, M, Harlan, M, Orlow, I, Yatabe, Y, Nafa, K, Ladanyi, M, Viale, A, Kris, MG, Riely, G, Miller, V, Klein, RJ, Matsuo, K, Pao, W Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. Clin Cancer Res, 16(2), 755-63, 2010.
- Jackman, D, Pao, W, Riely, GJ, Engelman, JA, Kris, MG, Jänne, PA, Lynch, T, Johnson, BE, Miller, VA Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol, 28(2), 357-60, 2010.
- Sun, YH, Fang, R, Gao, B, Han, XK, Zhang, JH, Pao, W, Chen, HQ, Ji, HB Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers. Acta Pharmacol Sin, 31(5), 647-8, 2010.
- Solomon, SB, Zakowski, MF, Pao, W, Thornton, RH, Ladanyi, M, Kris, MG, Rusch, VW, Rizvi, NA Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. AJR Am J Roentgenol, 194(1), 266-9, 2010.
- Yeo, WL, Riely, GJ, Yeap, BY, Lau, MW, Warner, JL, Bodio, K, Huberman, MS, Kris, MG, Tenen, DG, Pao, W, Kobayashi, S, Costa, DB Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol, 5(7), 1048-53, 2010.
- Weiss, J, Sos, ML, Seidel, D, Peifer, M, Zander, T, Heuckmann, JM, Ullrich, RT, Menon, R, Maier, S, Soltermann, A, Moch, H, Wagener, P, Fischer, F, Heynck, S, Koker, M, Schöttle, J, Leenders, F, Gabler, F, Dabow, I, Querings, S, Heukamp, LC, Balke-Want, H, Ansén, S, Rauh, D, Baessmann, I, Altmüller, J, Wainer, Z, Conron, M, Wright, G, Russell, P, Solomon, B, Brambilla, E, Brambilla, C, Lorimier, P, Sollberg, S, Brustugun, OT, Engel-Riedel, W, Ludwig, C, Petersen, I, Sänger, J, Clement, J, Groen, H, Timens, W, Sietsma, H, Thunnissen, E, Smit, E, Heideman, D, Cappuzzo, F, Ligorio, C, Damiani, S, Hallek, M, Beroukhim, R, Pao, W, Klebl, B, Baumann, M, Buettner, R, Ernestus, K, Stoelben, E, Wolf, J, Nürnberg, P, Perner, S, Thomas, RK Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med, 2(62), 62ra93, 2010.
- Pao, W, Iafrate, AJ, Su, Z Genetically informed lung cancer medicine. J Pathol, 2010.
- Clarke, JL, Pao, W, Wu, N, Miller, VA, Lassman, AB High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol, 99(2), 283-6, 2010.
- Sun, Y, Ren, Y, Fang, Z, Li, C, Fang, R, Gao, B, Han, X, Tian, W, Pao, W, Chen, H, Ji, H Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol, 28(30), 4616-20, 2010.
- Price, KA, Azzoli, CG, Krug, LM, Pietanza, MC, Rizvi, NA, Pao, W, Kris, MG, Riely, GJ, Heelan, RT, Arcila, ME, Miller, VA Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. J Thorac Oncol, 5(10), 1623-9, 2010.
- Pao, W, Chmielecki, J Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer, 10(11), 760-74, 2010.
- Veeriah, S, Taylor, BS, Meng, S, Fang, F, Yilmaz, E, Vivanco, I, Janakiraman, M, Schultz, N, Hanrahan, AJ, Pao, W, Ladanyi, M, Sander, C, Heguy, A, Holland, EC, Paty, PB, Mischel, PS, Liau, L, Cloughesy, TF, Mellinghoff, IK, Solit, DB, Chan, TA Somatic mutations of the Parkinson''s disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet, 42(1), 77-82, 2010.
- Gao, B, Sun, Y, Zhang, J, Ren, Y, Fang, R, Han, X, Shen, L, Liu, XY, Pao, W, Chen, H, Ji, H Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas. J Thorac Oncol, 5(8), 1130-5, 2010.
- Chmielecki, J, Peifer, M, Jia, P, Socci, ND, Hutchinson, K, Viale, A, Zhao, Z, Thomas, RK, Pao, W Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. Nucleic Acids Res, 38(20), 6985-96, 2010.
- Redente, EF, Dwyer-Nield, LD, Merrick, DT, Raina, K, Agarwal, R, Pao, W, Rice, PL, Shroyer, KR, Malkinson, AM Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization. Am J Pathol, 176(6), 2972-85, 2010.
- Girard, N, Deshpande, C, Azzoli, CG, Rusch, VW, Travis, WD, Ladanyi, M, Pao, W Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. Chest, 137(1), 46-52, 2010.
- Chitale D*, Gong Y*, Taylor BS*, Broderick S*, Brennan C, Somwar R, Golas B, Wang L, Motoi N, Szoke J, Reinersman JM, Major J, Sander C, Seshan VE, Zakowski MF, Rusch V, Pao W, Gerald W, Ladanyi M. "An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors.." Oncogene, (28), 2773-2783, 2009.
- Girard N, Shen R, Guo T, Zakowski MF, Heguy A, Riely GJ, Huang J, Lau C, Lash AE, Ladanyi M, Viale A, Antonescu CR, Travis WD, Rusch VW, Kris MG, Pao W. "Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.." Clinical Cancer Research, (15), 6790-6799, 2009.
- Girard N, Deshpande C, Lau C, Finley D, Rusch V, Pao W, Travis WD. "Comprehensive histologic assessment helps to differentiate multiple lung primary non-small cell carcinomas from metastases.." Am J Surg Pathol, (33), 1752-1764, 2009.
- Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, Koutcher JA, Spassove M, Ouerfelli O, Mellinghoff IK, Zakowski MF, Politi KA, Pao W. "Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.." J Clin Invest, (119), 3000-3010, 2009.
- Girard N, Ostrovnaya I, Lau C, Park B, Ladanyi M, Finley D, Deshpande C, Rusch V, Orlow I, Travis WD, Pao W*, Begg CB*. "Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers.." Clinical Cancer Research, (15), 5184-5190, 2009.
- Gong Y, Yao E, Shen R, Goel A, Arcila M, Teruya-Feldstein J, Zakowski M, Frankel S, Peifer M, Thomas RK, Ladanyi M, and Pao W. "High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507).." PLoS One, (4), 7273, 2009.
- Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, Heynck S, Stückrath I, Weiss J, Fischer F, Michel K, Goel A, Regales L, Politi KA, Perera S, Getlik M, Heukamp LC, Ansén S, Zander T, Beroukhim R, Kashkar H, Shokat KM, Sellers WR, Rauh D, Orr C, Hoeflich KP, Friedman L, Wong KK, Pao W, Thomas RK. "Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.." Proc Natl Acad Scie USA, (106), 18351-18356, 2009.
- Pao, W, Kris, MG, Iafrate, AJ, Ladanyi, M, Jänne, PA, Wistuba, II, Miake-Lye, R, Herbst, RS, Carbone, DP, Johnson, BE, Lynch, TJ Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res, 15(17), 5317-22, 2009.
- Zakowski, MF, Hussain, S, Pao, W, Ladanyi, M, Ginsberg, MS, Heelan, R, Miller, VA, Rusch, VW, Kris, MG Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. Arch Pathol Lab Med, 133(3), 470-7, 2009.
- Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, Michel K, Peifer M, Mermel C, Girard L, Peyton M, Gazdar A, Minna JD, Garraway LA, Kashkar H, Pao W, Meyerson M, Thomas RK "PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.." Cancer Research, 693256-3261, 2009.
- Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, Mischel PS, Sander C, Taylor B, Schultz N, Major J, Heguy A, Fang F, Mellinghoff IK, Chan TA. "The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.." Proc Natl Acad Sci USA, (106), 9435-9440, 2009.
- Bean, J, Riely, GJ, Balak, M, Marks, JL, Ladanyi, M, Miller, VA, Pao, W Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res, 14(22), 7519-25, 2008.
- Lyustikman, Y, Momota, H, Pao, W, Holland, EC Constitutive activation of Raf-1 induces glioma formation in mice. Neoplasia, 10(5), 501-10, 2008.
- Marks, JL, Golas, B, Kirchoff, T, Miller, VA, Riely, GJ, Offit, K, Pao, W EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations. J Thorac Oncol, 3(7), 805, 2008.
- Li, AR, Chitale, D, Riely, GJ, Pao, W, Miller, VA, Zakowski, MF, Rusch, V, Kris, MG, Ladanyi, M EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn, 10(3), 242-8, 2008.
- Costa, DB, Nguyen, KS, Cho, BC, Sequist, LV, Jackman, DM, Riely, GJ, Yeap, BY, Halmos, B, Kim, JH, Jänne, PA, Huberman, MS, Pao, W, Tenen, DG, Kobayashi, S Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res, 14(21), 7060-7, 2008.
- Riely, GJ, Kris, MG, Rosenbaum, D, Marks, J, Li, A, Chitale, DA, Nafa, K, Riedel, ER, Hsu, M, Pao, W, Miller, VA, Ladanyi, M Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res, 14(18), 5731-4, 2008.
- Pratilas, CA, Hanrahan, AJ, Halilovic, E, Persaud, Y, Soh, J, Chitale, D, Shigematsu, H, Yamamoto, H, Sawai, A, Janakiraman, M, Taylor, BS, Pao, W, Toyooka, S, Ladanyi, M, Gazdar, A, Rosen, N, Solit, DB Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res, 68(22), 9375-83, 2008.
- Ladanyi, M, Pao, W Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol, 21 Suppl 2S16-22, 2008.
- Miller, VA, Riely, GJ, Zakowski, MF, Li, AR, Patel, JD, Heelan, RT, Kris, MG, Sandler, AB, Carbone, DP, Tsao, A, Herbst, RS, Heller, G, Ladanyi, M, Pao, W, Johnson, DH Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol, 26(9), 1472-8, 2008.
- Azzoli, CG, Park, BJ, Pao, W, Zakowski, M, Kris, MG Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise. J Thorac Oncol, 3(1), 84-93, 2008.
- Marks, JL, Gong, Y, Chitale, D, Golas, B, McLellan, MD, Kasai, Y, Ding, L, Mardis, ER, Wilson, RK, Solit, D, Levine, R, Michel, K, Thomas, RK, Rusch, VW, Ladanyi, M, Pao, W Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res, 68(14), 5524-8, 2008.
- Marks, JL, Broderick, S, Zhou, Q, Chitale, D, Li, AR, Zakowski, MF, Kris, MG, Rusch, VW, Azzoli, CG, Seshan, VE, Ladanyi, M, Pao, W Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol, 3(2), 111-6, 2008.
- Yang, CH, Yu, CJ, Shih, JY, Chang, YC, Hu, FC, Tsai, MC, Chen, KY, Lin, ZZ, Huang, CJ, Shun, CT, Huang, CL, Bean, J, Cheng, AL, Pao, W, Yang, PC Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol, 26(16), 2745-53, 2008.
- Weir, BA, Woo, MS, Getz, G, Perner, S, Ding, L, Beroukhim, R, Lin, WM, Province, MA, Kraja, A, Johnson, LA, Shah, K, Sato, M, Thomas, RK, Barletta, JA, Borecki, IB, Broderick, S, Chang, AC, Chiang, DY, Chirieac, LR, Cho, J, Fujii, Y, Gazdar, AF, Giordano, T, Greulich, H, Hanna, M, Johnson, BE, Kris, MG, Lash, A, Lin, L, Lindeman, N, Mardis, ER, McPherson, JD, Minna, JD, Morgan, MB, Nadel, M, Orringer, MB, Osborne, JR, Ozenberger, B, Ramos, AH, Robinson, J, Roth, JA, Rusch, V, Sasaki, H, Shepherd, F, Sougnez, C, Spitz, MR, Tsao, MS, Twomey, D, Verhaak, RG, Weinstock, GM, Wheeler, DA, Winckler, W, Yoshizawa, A, Yu, S, Zakowski, MF, Zhang, Q, Beer, DG, Wistuba, II, Watson, MA, Garraway, LA, Ladanyi, M, Travis, WD, Pao, W, Rubin, MA, Gabriel, SB, Gibbs, RA, Varmus, HE, Wilson, RK, Lander, ES, Meyerson, M Characterizing the cancer genome in lung adenocarcinoma. Nature, 450(7171), 893-8, 2007.
- Regales, L, Balak, MN, Gong, Y, Politi, K, Sawai, A, Le, C, Koutcher, JA, Solit, DB, Rosen, N, Zakowski, MF, Pao, W Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS ONE, 2(8), e810, 2007.
- Pao, W, Ladanyi, M Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res, 13(17), 4954-5, 2007.
- Gong, Y, Somwar, R, Politi, K, Balak, M, Chmielecki, J, Jiang, X, Pao, W Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med, 4(10), e294, 2007.
- Bean, J, Brennan, C, Shih, JY, Riely, G, Viale, A, Wang, L, Chitale, D, Motoi, N, Szoke, J, Broderick, S, Balak, M, Chang, WC, Yu, CJ, Gazdar, A, Pass, H, Rusch, V, Gerald, W, Huang, SF, Yang, PC, Miller, V, Ladanyi, M, Yang, CH, Pao, W MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A, 104(52), 20932-7, 2007.
- Marks, JL, McLellan, MD, Zakowski, MF, Lash, AE, Kasai, Y, Broderick, S, Sarkaria, IS, Pham, D, Singh, B, Miner, TL, Fewell, GA, Fulton, LL, Mardis, ER, Wilson, RK, Kris, MG, Rusch, VW, Varmus, H, Pao, W Mutational analysis of EGFR and related signaling pathway genes in lung Adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS ONE, 2(5), e426, 2007.
- Gao, SP, Mark, KG, Leslie, K, Pao, W, Motoi, N, Gerald, WL, Travis, WD, Bornmann, W, Veach, D, Clarkson, B, Bromberg, JF Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest, 117(12), 3846-56, 2007.
- Milton, DT, Riely, GJ, Azzoli, CG, Gomez, JE, Heelan, RT, Kris, MG, Krug, LM, Pao, W, Pizzo, B, Rizvi, NA, Miller, VA Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer, 110(3), 599-605, 2007.
- Riely, GJ, Kris, MG, Zhao, B, Akhurst, T, Milton, DT, Moore, E, Tyson, L, Pao, W, Rizvi, NA, Schwartz, LH, Miller, VA Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res, 13(17), 5150-5, 2007.
- Milton, DT, Azzoli, CG, Heelan, RT, Venkatraman, E, Gomez, JE, Kris, MG, Krug, LM, Pao, W, Rizvi, NA, Dunne, M, Miller, VA A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer, 107(5), 1034-41, 2006.
- Christiani, DC, Pao, W, DeMartini, JC, Linnoila, RI, Malkinson, AM, Onn, A, Politi, KA, Sharp, M, Wong, KK, Kim, K BAC consensus conference, November 4-6, 2004: epidemiology, pathogenesis, and preclinical models. J Thorac Oncol, 1(9 Suppl), S2-7, 2006.
- Riely, GJ, Pao, W, Pham, D, Li, AR, Rizvi, N, Venkatraman, ES, Zakowski, MF, Kris, MG, Ladanyi, M, Miller, VA Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res, 12(3 Pt 1), 839-44, 2006.
- Pao, W Defining clinically relevant molecular subsets of lung cancer. Cancer Chemother Pharmacol, 58 Suppl 1s11-5, 2006.
- Politi, K, Zakowski, MF, Fan, PD, Schonfeld, EA, Pao, W, Varmus, HE Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev, 20(11), 1496-510, 2006.
- Milton, DT, Riely, GJ, Pao, W, Miller, VA, Kris, MG, Heelan, RT Molecular on/off switch. J Clin Oncol, 24(30), 4940-2, 2006.
- Pao, W Monitoring EGFR-mutant lung cancers by means of the blood. J Thorac Oncol, 1(3), 199-200, 2006.
- Balak, MN, Gong, Y, Riely, GJ, Somwar, R, Li, AR, Zakowski, MF, Chiang, A, Yang, G, Ouerfelli, O, Kris, MG, Ladanyi, M, Miller, VA, Pao, W Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res, 12(21), 6494-501, 2006.
- Riely, GJ, Politi, KA, Miller, VA, Pao, W Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res, 12(24), 7232-41, 2006.
- Pham, D, Kris, MG, Riely, GJ, Sarkaria, IS, McDonough, T, Chuai, S, Venkatraman, ES, Miller, VA, Ladanyi, M, Pao, W, Wilson, RK, Singh, B, Rusch, VW Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol, 24(11), 1700-4, 2006.
- Pao, W, Miller, VA, Politi, KA, Riely, GJ, Somwar, R, Zakowski, MF, Kris, MG, Varmus, H Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med, 2(3), e73, 2005.
- Riely, GJ, Pao, W Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important. Cancer Biol Ther, 4(10), 1096-7, 2005.
- Ren, GP, Wang, TY, Pan, QL, Pao, W, Huai, J Epidermal growth factor receptor mutations detected in tumors from Chinese "never smokers" with lung adenocarcinoma. Chin Med J (Engl), 118(9), 769-71, 2005.
- Pao, W, Miller, VA Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol, 23(11), 2556-68, 2005.
- Pao, W, Ladanyi, M, Miller, VA, , Erlotinib in lung cancer. N Engl J Med, 353(16), 1739-41; author reply 1739-41, 2005.
- Carter, TA, Wodicka, LM, Shah, NP, Velasco, AM, Fabian, MA, Treiber, DK, Milanov, ZV, Atteridge, CE, Biggs, WH, Edeen, PT, Floyd, M, Ford, JM, Grotzfeld, RM, Herrgard, S, Insko, DE, Mehta, SA, Patel, HK, Pao, W, Sawyers, CL, Varmus, H, Zarrinkar, PP, Lockhart, DJ Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A, 102(31), 11011-6, 2005.
- Pao, W, Wang, TY, Riely, GJ, Miller, VA, Pan, Q, Ladanyi, M, Zakowski, MF, Heelan, RT, Kris, MG, Varmus, HE KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med, 2(1), e17, 2005.
- Lassman, AB, Rossi, MR, Raizer, JJ, Razier, JR, Abrey, LE, Lieberman, FS, Grefe, CN, Lamborn, K, Pao, W, Shih, AH, Kuhn, JG, Wilson, R, Nowak, NJ, Cowell, JK, DeAngelis, LM, Wen, P, Gilbert, MR, Chang, S, Yung, WA, Prados, M, Holland, EC Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res, 11(21), 7841-50, 2005.
- Varmus, H, Pao, W, Politi, K, Podsypanina, K, Du, YC Oncogenes come of age. Cold Spring Harb Symp Quant Biol, 701-9, 2005.
- Shah, NT, Kris, MG, Pao, W, Tyson, LB, Pizzo, BM, Heinemann, MH, Ben-Porat, L, Sachs, DL, Heelan, RT, Miller, VA Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol, 23(1), 165-74, 2005.
- Pan, Q, Pao, W, Ladanyi, M Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn, 7(3), 396-403, 2005.
- Pao, W, Miller, VA, Kris, MG ''Targeting'' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Semin Cancer Biol, 14(1), 33-40, 2004.
- Miller, VA, Kris, MG, Shah, N, Patel, J, Azzoli, C, Gomez, J, Krug, LM, Pao, W, Rizvi, N, Pizzo, B, Tyson, L, Venkatraman, E, Ben-Porat, L, Memoli, N, Zakowski, M, Rusch, V, Heelan, RT Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol, 22(6), 1103-9, 2004.
- Pao, W, Miller, V, Zakowski, M, Doherty, J, Politi, K, Sarkaria, I, Singh, B, Heelan, R, Rusch, V, Fulton, L, Mardis, E, Kupfer, D, Wilson, R, Kris, M, Varmus, H EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A, 101(36), 13306-11, 2004.
- Pao, W, Miller, VA, Venkatraman, E, Kris, MG Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt. J Natl Cancer Inst, 96(15), 1117-9, 2004.
- Cong, F, Zhang, J, Pao, W, Zhou, P, Varmus, H A protein knockdown strategy to study the function of beta-catenin in tumorigenesis. BMC Mol Biol, 410, 2003.
- Zhang, F, Pao, W, Umphress, SM, Jakowlew, SB, Meyer, AM, Dwyer-Nield, LD, Nielsen, LD, Takeda, K, Gelfand, EW, Fisher, JH, Zhang, L, Malkinson, AM, Mason, RJ Serum levels of surfactant protein D are increased in mice with lung tumors. Cancer Res, 63(18), 5889-94, 2003.
- Pao, W, Klimstra, DS, Fisher, GH, Varmus, HE Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance. Proc Natl Acad Sci U S A, 100(15), 8764-9, 2003.
- Khan, KM, Pao, W, Kendler, J Epidural abscess and vertebral osteomyelitis caused by Listeria monocytogenes: case report and literature review. Scand J Infect Dis, 33(9), 714-6, 2001.
- Girard N, Ostrovnaya I, Lau C, Park B, Ladanyi M, Finley D, Deshpande C, Rusch V, Orlow I, Travis WD, Pao W*, Begg CB*. "Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers.." Clinical Cancer Research, (15), 5184-5190, 2001.
- Pao, W, Duncan, KO, Bolognia, JL, Carroll, CB, Hotez, PJ, Bessen, DE Numerous eruptive lesions of panniculitis associated with group A streptococcus bacteremia in an immunocompetent child. Clin Infect Dis, 27(3), 430-3, 1998.
- Wen, L, Barber, DF, Pao, W, Wong, FS, Owen, MJ, Hayday, A Primary gamma delta cell clones can be defined phenotypically and functionally as Th1/Th2 cells and illustrate the association of CD4 with Th2 differentiation. J Immunol, 160(4), 1965-74, 1998.
- Passoni, L, Hoffman, ES, Kim, S, Crompton, T, Pao, W, Dong, MQ, Owen, MJ, Hayday, AC Intrathymic delta selection events in gammadelta cell development. Immunity, 7(1), 83-95, 1997.
- Mallick-Wood, CA, Pao, W, Cheng, AM, Lewis, JM, Kulkarni, S, Bolen, JB, Rowley, B, Tigelaar, RE, Pawson, T, Hayday, AC Disruption of epithelial gamma delta T cell repertoires by mutation of the Syk tyrosine kinase. Proc Natl Acad Sci U S A, 93(18), 9704-9, 1996.
- Pao, W, Wen, L, Smith, AL, Gulbranson-Judge, A, Zheng, B, Kelsoe, G, MacLennan, IC, Owen, MJ, Hayday, AC Gamma delta T cell help of B cells is induced by repeated parasitic infection, in the absence of other T cells. Curr Biol, 6(10), 1317-25, 1996.
- Dianda, L, Gulbranson-Judge, A, Pao, W, Hayday, AC, MacLennan, IC, Owen, MJ Germinal center formation in mice lacking alpha beta T cells. Eur J Immunol, 26(7), 1603-7, 1996.
- Wen, L, Pao, W, Wong, FS, Peng, Q, Craft, J, Zheng, B, Kelsoe, G, Dianda, L, Owen, MJ, Hayday, AC Germinal center formation, immunoglobulin class switching, and autoantibody production driven by "non alpha/beta" T cells. J Exp Med, 183(5), 2271-82, 1996.
- Cheng, AM, Rowley, B, Pao, W, Hayday, A, Bolen, JB, Pawson, T Syk tyrosine kinase required for mouse viability and B-cell development. Nature, 378(6554), 303-6, 1995.
- Kyes, S, Pao, W, Hayday, A Influence of site of expression on the fetal gamma delta T-cell receptor repertoire. Proc Natl Acad Sci U S A, 88(17), 7830-3, 1991.


text:
If you don't mind the larger size and different color, this mirror is OK. It looks more masculine than antique-y. I hope I can find a use for it, because I am sure shipping it back will be expensive. This is my second purchase from overstock where the product differed significantly from the description.
Nice mirror hanging over fireplace. Heavy and sturdy and very good quality
This is a very nice mirror, BUT it does not look like the picture on the website. I don't know why overstock wouldn't take a picture of the actual product, and not use a computerized image. That being said, I still really like the mirror, and it looks great above our fireplace / mantle. Like other people said, the outline around the mirror is black, not white. And the edge of the mirror has a bronze/gold tint (kinda like a brushed nickel.)
Mirror was not as pictured. Inside ring around mirror was black not white or silver. Item was returned.
this mirror is good quality and looks sharp in person, the only problem is i needed a 30 inch mirror for a small bathroom and the mirror is actually 36 inches round, keep this in mind when ordering, otherwise it is a nice product and great value for the money.
great wall mirror. good look and finish to it. i was concerned about the weight but it is actually pretty light. And although i would have preferred the hooks on the back to be a little wider or user friendly it was mounted fairly easily.
This seems to be an attractive and well-made mirror. However, the picture is very inaccurate. I thought the mirror was beveled and that is why there is a smaller circle within the frame. In fact, when it arrived, the area between the mirror and the frame is BLACK. I think it would be more attractive if beveled, but it is growing on me, so I decided to keep it. I think this picture is very deceptive, though. When I look at it now, it is as if that area is simply missing from the picture.
This mirror looks amazing in our dining room! We wanted something upscale and it looks perfect.
Usually leaves our warehouse in 1-2 business days. *
Items must be returned in new or unused condition and contain all original materials included with the shipment. More details
FINAL SALE EXCLUSION: Items marked as FINAL SALE are not returnable unless the problem you experience is the result of our error.
Our standard shipping method is ground shipping. We also offer expedited shipping for most items. Your final shipping cost and estimated delivery timeframe will be available at checkout.
Standard shipping details
Expedited shipping details
* For your safety, some orders go through our loss prevention department. If we select your order for this process, we will immediately notify you that there may be up to a 3-day delay on your order.
** Most Oversize orders are delivered within 1-4 weeks. Some orders may take 6 weeks to be delivered.


text:
Thursday, 05 September 2013 00:00
Aspiring basketball players got the chance to hone their skills at the Bunky Reid All Stars Basketball Camp last week which was held at the Westbury Sports Center. The camp was run by Michael Jackson, a former All-Long Island athlete from Westbury High School, who ultimately went on to play collegiately at Division-I Hofstra.
"The best part is the joy of seeing the kid's interactions with one another and the smiles on their face when they make a good play," said Jackson, who oversees all aspects of the eight hour camp.
The boys, who ranged from ages five to 15, gathered in the morning to participate in drills which improved their skills in regards to offense, defense and passing. After, they split up the age groups and played competitive games which allowed them to put their newly refined skills to the test.
The camp has taken place each year since 2008, and Jackson believes it has been extremely successful in both teaching the younger children how to play as a team, while also developing their skills to play at the next level. The camp has been extremely beneficial to young basketball players in the past, and Jackson has allowed the kids to develop their skills while not being in an overwhelming atmosphere. Five of his former players have gone on to play at the collegiate level in recent years. Sheldon Hagigal (St. Francis), Ahmad Reid (Stony Brook), Brandon Williams (Molloy), Matt McLeod (Molloy) and Lamar Herron (New Paltz) have all used their time at the Bunky Reid camp to become well-rounded athletes and young men.
Jackson also runs the Amateur Athletic Union (AAU) boys and girls teams that have had terrific success on the court. The teams had their playoffs at the "Yes We Can" Center last week and championship game on Friday, August 30. The teams have been playing games all summer at the center and Bunky Reid Park.


text:
This website uses cookies. By continuing to browse RFU.com you are agreeing to our use of cookies. Find out more by viewing our privacy and cookie policy.
Skip to content
You are here:
Previous section: World Rugby Museum
The World Rugby Museum's latest special exhibition celebrates the life and work of pop-artist and sculptor Gerald Laing (1936-2011).
Gerald Laing first made his name in the 1960s among a group of emerging American pop artists that included Roy Lichtenstein, Andy Warhol, Robert Indiana and Jim Rosenquist. In later years he turned his hand to sculpture and left his imprint all over Twickenham Stadium in the shape of "The Four Players" and the monumental "Core Values" line-out sculpture that stands outside the stadium.
The exhibition, Core Values: The Life and Work of Gerald Laing, runs throughout the QBE Internationals and 2014 RBS 6 Nations period. On public display for the first time will be a selection of Gerald's conceptual drawings and the actual resin moulds used to cast the five large-scale players' heads from the Core Values sculpture, which visitors will be invited to touch and feel.
The exhibition will explore:
Museum Curator Michael Rowe said: "We are delighted to open this exciting new exhibition at the World Rugby Museum. The 'Core Values' line-out sculpture is one of Twickenham's iconic attractions, so it's great that we can tell people the story behind it and about the man who created it."
Farquhar Laing, the artist's son said: "'Core Values' was one of my father's most important commissions, and he would have been delighted by this tribute to his work. This thoughtfully curated exhibition shows just how meticulous he was as an artist; it's a fine celebration of the making of a remarkable sculpture."
Download the following links for more information about the exhibition:
Gerald Laing: Life and Works (PDF 832kB)
The Four Players (1994) (PDF 920kB)
Core Values sculpture (2009) PDF 8.54MB)
The Core Values of the Rugby Football Union (PDF 1.38MB)
Tickets for the museum are £7 for adults and £5 for concessions, or £15 and £9 when combined with a Twickenham Stadium Tour. Please contact the World Rugby Museum on 020 8892 8877 or email@example.com for details.


text:
Presidential Announcement: President Cristina Fernández de Kirchner made her first public appearance since December last night. In a televised speech, she announced the launch of a programme of student allowances for people between the ages of 18 and 24 who are unemployed, employed in the informal labour market, or earn less than the minimum wage ($3,600). Beneficiaries of the allowance will need to submit certificates in March, July, and November of each year showing that they are enrolled in an educational institution of any level, and will have to carry out a yearly health check in order to receive the $600 monthly payment. The programme, called Progresar, is seen as an extension of the Asignación Universal por Hijo (AUH), will have an estimated cost of $11.2bn, and will potentially reach 1.5m people. "Young people who don't work or study are the children of neoliberalism, they're the children of parents who didn't have a job or who lost it, and weren't educated in the culture of labour. This is why they need the state to move forward," said the president. She also confirmed she will travel to Cuba to participate in the Community of Latin American and Caribbean States (CELAC) summit on 28th and 29th January.
Devaluation: The Argentine peso lost 12% of its value today, closing at $8 per US dollar, after reaching a peak of $8.31 at around noon. The Central Bank abstained from trading in the exchange market for most of the day, letting the local currency weaken dramatically for the second day in a row. Yesterday, the peso had closed at $7.14 per US dollar, up $0.24 from the previous day, the highest daily rate of devaluation since 2002. With today's move, the peso has depreciated by 22.7% since the beginning of the year. On the parallel -or 'blue'- market, the US dollar was selling at approximately $13, a 62.5% gap between both markets.
Overseas Shopping Restrictions: Tax agency AFIP informed today through a statement on its website the exceptions to the restrictions in overseas purchases announced yesterday. Books, prescribed medicines, works of art, and certain personal needs items will not be subjected to the limit of two purchases per year set by AFIP.


text:
Reebok Men's Minnesota Wild Spray Booth Hunter Green T-Shirt
$15.97 $20.00*
Save $4.03 (20%)
Product Information:
Root for your team in the paint when you sport the Reebok® Men's Minnesota Wild Spray Booth T-Shirt. Wild graphics adorn this team-colored tee in a distressed, spray paint print so you can combine your hockey pride with your bold style. A crew neckline offers a standard, comfortable fit whether you're on the doorstep or in the stands. Stick with your team through the ebbs and flows of the season when you dress in this Reebok® tee.
- Reebok® team-colored tee
- Team graphics in distressed, spray paint effect to show fandom
- Crew neckline for a standard fit and feel
- Reebok® brandmark for authenticity
- Officially licensed by the NHL®
- Reebok
Country of Origin: ImportedWeb ID: 21600386


text:
How Amazon Keeps Cutting AWS Prices: Cheapskate Culture
Re:Fly Economy - tragic! (146 comments)
For certain services, commoditization makes it very unlikely that your internal organization will be able to compete in cost/quality ratios with specialized service providers. Example: Banks used to manage all aspects of their networking due to downtime impact, nowadays redundant providers can deliver networking with adequate SLAs (contractual, penalised) at lower cost than their internal staff, are there any banks that still lay their own fiber?


text:
- Quicklinks
What Is, What Was, and What Will Be: The Progressive Movement in the 21st Century
Speaker: Brian Rothenberg, executive director at Progress Ohio.
Date: Friday, April 5, noon-1 p.m.
Location: The Ohio State University at Marion
Maynard Hall, Guthery Community Room
1465 Mount Vernon Avenue
Marion, Ohio 43302
The History Program at Ohio State Marion, the Harding/Thomas Endowment Fund, and Fahey Bank invite you to the Annual Norman Thomas Memorial Lecture in the Guthery Community Room in Maynard Hall, Marion Campus, Friday 5 April 2013 Noon to 1 PM
This year's speaker is: Brian Rothenberg- Executive Director, ProgressOhio, who will deliver a talk titled: What Is, What Was, and What Will Be: The Progressive Movement in the 21st Century
Brian Rothenberg is the Executive Director of ProgressOhio, which he founded in 2006. Under his leadership, ProgressOhio has become the state's largest progressive advocacy organization, working for a variety of causes including reducing gun violence, passing same-sex marriage legislation, exposing corporate influence in government, and advocating common-sense solutions to state and federal budget challenges.
Throughout the twentieth century, Norman Thomas advocated for progressive change on issues ranging from civil rights to environmental protection, economic equality and pacifism. Despite major social upheaval in the past century, the progressive movement still faces significant challenges. Learning from the lessons of what was during Norman Thomas' lifetime, we will examine the political realities of what is today, and evaluate what can and will be in the future.


text:
"Tum Gujrati log kitne cute hote hai ... par tum log ka khaana itna khatarnaak kyun hota hai ... Dhokla Faafda Handva Thepla ... aise lagta hai koi missiles hai...."
Remember Kareena Kapoor's dialogue from the film "3 Idiots"? Well, I of course agree completely with the very first senetence!!;-) As a food blogger, when I hear these words, I do calculations in my mind - Dhokla - tick, Handva - tick, Thepla - tick, Khandvi - tick, Faafda - not yet, Undhiyu - not yet! - what , I havent' blogged about Undhiyu yet? What kind of Gujarati daughter-in-law am I? Well, but to be honest, I have prolonged posting about Undhiyu because I do not get the right winter vegetables here. I had seen a frozen "Undhiyu vegetable" packet in the freezer section of Indian stores, but I was very disappointed with the result. Finally, I collected, the individually frozen Undhiyu vegetables and tried to recreate the recipe. During winter, you get beautiful Unhiyu vegetables in Mumbai. I had to be content with these frozen veggies.
Another stumbling block for not blogging Undhiyu yet was that I have several versions of the family recipe. So after gathering the correct ingredients, I decided to make Undhiyu - 1.
Winter Special Gujarati Mixed Vegetables
1 packet Surti Papdi, whole (Frozen)
1 packet Surti Papdi, Lilva/beans (frozen)
1 packet Toovar Lilva (Frozen)
1 packet ratalu (Frozen)
1 big corn on cob, cut into 6 chunks
5-6 small eggplants
5-6 small potatoes
1 ripe yet firm banana, cut into 6 thick rounds
1 1/2 cups Methi Muthiya
*Grind/Crumble coarsely
1/2 cup sev
*Grind to a coarse paste
1 bunch cilantro
4 - 5 garlic cloves - preferably with greens
2" ginger, peeled
4-5 green chilies
salt to taste
1 tbsp sugar
1 tbsp lemon juice
1 tbsp Gujarati Garam Masala
1 tbsp coriander-cumin powder/dhana jiru
1 tsp mild chili powder
1 cup freshly scraped coconut
1/2 cup cilantro, chopped
1 tbsp kasoori methi
*Ground paste
* Coarsely crumbled Sev
1 tbsp oil
1/2 tsp owa/ajmo/ajwain
1 tbsp white sesame seeds
Suggested Accompaniment
Aamras/Keri nu Rus
0. Rinse/Thaw vegetables. Cut a cross on each potato and eggplant and banana. Stuff the masala stuffing inside potatoes, eggplant and banana. Keep the remaining stuffing.
1. Heat a pressure cooker. Add oil and ajwain/Ajmo/Owa and sesame seeds.
2. As they stat spluttering, place corn, stuffed eggplants and potatoes. On top of them place the remaining vegetables. Do not add bananas and muthiyas at this point. Sprinkle all the remaining stuffing and 2 cups water.
3. Pressure cook for 2 whistles.
4. Now add muthiyas and bananas.
5. Cover and let it cook for 1 hour or so.
Note -
1. Traditionally lot more oil is added for cooking this winter special delicacy.
2. If possible, use goradu/konfal/kand mul which is a purple colored Indian root vegetable.
Print Page


text:
By Daniel Cowan
4 Comments
Mar 21st, 2014
Best ever Arsène XI's are everywhere at the moment and after watching a few people meltdown at mine on Twitter – which was strange in and o...
By Daniel Cowan
5 Comments
Jul 11th, 2013
Since joining Arsenal, Arsène Wenger has unearthed or brought through some immense talents to the first team; often finding diamonds in the rough or fu...
By Daniel Cowan
23 Comments
Oct 14th, 2012
It's been a while since my last post and this is only a short one so please forgive me if you had planned for one of my epics. I had planned to c...
By Daniel Cowan
15 Comments
Aug 17th, 2012
The new season is upon us and to celebrate I want to have a look forward and a look back at the same time. Many of you regulars follow me on twitter an...
By Daniel Cowan
98 Comments
Aug 6th, 2012
The year is 1999 and Arsenal have just finished the season without a trophy. They have been comprehensively beaten by an inspired Chelsea by 5 goals to...
By Cian Boyling
11 Comments
May 28th, 2012
Today at 'North London Is Red' I am delighted to welcome my first ever guest blogger, Cian Boyling (@ciansblog). Cian is a young up and coming blogger ...
By Daniel Cowan
9 Comments
May 17th, 2012
Okay let us imagine that we are super lucky and manage to sell all of our "dead wood" (see my post on end of season fire sale) which I pers...
By Daniel Cowan
9 Comments
May 11th, 2012
Earlier this week I focused on the financial aspects of Arsenal's trophy drought, in particular the correlation between Arsenal being unable to c...
By Daniel Cowan
0 Comments
Apr 30th, 2012
Pep Guardiola has announced his decision to leave Barcelona at the end of the season, a decision he says had been made in his mind as early as Septembe...


text:
Arc Makes Programs Shorter
Businessman and Lisp enthusiast Paul Graham presented the initial version of the Arc programming language. Graham points in particular to the brevity of Arc source code and has launched a programming language competition.
The release announcement describes Arc as a new dialect of Lisp which is still not complete, but usable. Currently Arc compiles source code with MzScheme, another member of the Lisp family, from which Arc borrows numeric and mathematical operations.
Graham sees Arc as a language for practically-oriented programmers who enjoy experimenting and need more freedom in program design. He refers to the language as "non-bureaucratic".
Above all, the language impresses with short source code files and parsing trees. After all, this is the whole point of a high-level language Paul Graham emphasizes. To add practical relevance to this, Graham is organizing a programming competition in the Arc Forum. The tasks describes a website that processes a simple form. Grahams Arc code for the complete application looks like this:
(defop said req (aform [w/link (pr "you said: " (arg _ "foo")) (pr "click here")] (input "foo") (submit)))
The Arc Challenge for fans of other programming languages is to create shorter source code for the program.
The Arc homepage has an installation guide and a short introduction to Arc programming, which does not assume prior knowledge of Lisp. Arc is licensed under the Perl Foundation's Artistic License 2.0.
Issue 170/2015
Buy this issue as a PDF
TOR Network Isn't So Anonymous
A new study says it is possible to unmask 81% of TOR users.
.NET Goes Open Source
Redmond joins the revolution by turning the .NET Core Runtime into a GitHub project.
Drupal Advisory Unleashes a Torrent of Attacks
Users only had 7 hours to update before the intrusions started.
HTML5 Gets Promoted to a Standard
It's official: The new web arrives
Linus Addresses Criticism for Harsh Language
Kernel king admits his tone has alienated volunteers, but says the demands of the process require directness.
New SSL Attack Lets a Malicious Listener Steal Session Cookies
New flaw in an old encryption scheme leaves the experts scrambling to disable SSL 3
Leading Open Source Coder Rants about Rants
Lennart Poettering wants to change the way Linux developers talk to each other.
HP Splits into Two Companies
Enterprise giant frees itself from ink and home PCs (and visa versa).
Mozilla Labs Shuts Down
Mozilla's product think tank sinks silently into history.
Internet Giants Launch Collaboration to Improve Open Source
TODO group will focus on open source tools in large-scale environments.


text:
Stockbridge shuts off water to DDA building
By Monroe Roark
Stockbridge officials have felt for some time that the Downtown Development Authority's claims in their ongoing legal dispute don't hold water.
Now it appears that the city has gotten the Henry County Water Authority involved.
The Times has confirmed that a call from City Hall resulted in a shutoff of water to the DDA's main building on North Park Place during the middle of last week. DDA officials had it reversed after showing the water authority a copy of the recorded deed proving that the DDA, not the city, owns the property.
In addition to the water being shut off, two meters had been padlocked at the request of the city. When DDA officials made the initial call to the water authority to make sure the bill had been paid, they were assured that the bill had been paid in full.
Upon receiving proof last Thursday morning as to the ownership of the property, the water authority apologized to the DDA and moved quickly to restore water service within two hours, according to a spokesperson.
The city official who made the first call asking for the water to be shut off reportedly claimed city ownership of the building, but the water authority responds to such disputes according to whomever is the title owner.
"We're sorry it happened, and we're glad the water authority got it back on," said DDA chairman J.T. Williams.
Kenneth Bernard, the DDA's attorney, sent a letter dated Friday to city attorney Michael Williams regarding the incident.
"It is my understanding that the City of Stockbridge contacted the Henry County Water Authority to have the water illegally locked at the meter for a building owned by the SDDA," he wrote. "Please allow this letter to serve as notice that this behavior is tortious interference with SDDA's business relationships and properties."
Bernard wrote that he hoped the city would avoid creating additional liability for taxpayers through such actions.
"Any future activity which interferes with SDDA properties will be met with swift legal response. While we appreciate your legal position, until same is litigated in the courts, it is inappropriate for your client to now suddenly interfere with the SDDA monies, properties, maintenance, and utilities at will."
The legal back-and-forth between the city and the DDA continues, as a recent motion for summary judgment was denied by Superior Court Judge Wade Crumbley but an amended and restated motion was filed July 2. A hearing on the new motion is scheduled for Aug. 7, according to J.T. Williams, at which time Crumbley is expected to either grant the request or call for a trial.
©Henry County Times, Inc.


text:
WEST PALM BEACH — — Lula Bell the camel wasn't expected to be all anyone was talking about after First Baptist Church's Christmas pageant dress rehearsal on Thursday evening.
But when a 1,000-pound animal and its rider topple into the pews, it's impossible not to take notice.
Maybe it was stage fright: The appearance at the West Palm Beach church on Flagler Drive was apparently Lula Bell's first gig.


text:
Immediate Release: April 3, 2005
Contact: Thomas Moore (email@example.com)
Phone: 607-777-2956
Binghamton men's lacrosse wins in a thrilling double overtime over Vermont 8-7
McNamara scores game-winner with 2:18 left in second sudden death overtime
Box Score
BINGHAMTON, N.Y.--Binghamton sophomore Matt McNamara (Oswego, N.Y.) scored the game winning goal with 2:18 left in the second sudden death overtime to lead Binghamton (1-5, 1-0 AE) over Vermont (2-4, 0-2 AE) 8-7 at a wet Alumni Stadium on Sunday afternoon. This was the home and conference opening game for the Bearcats, who have not lost a regular season conference game since the 2003 season when they lost to Hartford 13-7, going 7-0 over the span.
Binghamton held a 3-2 led after the first quarter with freshman Stephen Smith (Canandaigua, N.Y.), sophomore Rob Williams (Fulton, N.Y.) and junior Matt DeCirce (Binghamton, N.Y.) each scoring in the first 15 minutes. Sophomore Jeff Santucci (Cicero, N.Y.) and McNamara assisted the second and third Bearcat goals. The second quarter opened with a Santucci goal which was assisted by McNamara at 13:41. Following that the quarter belonged to the Catamounts, who outscored Binghamton 2-0 and outshot them 8-2 to tie the game at 4-4 at the half.
In the opening minute of the third quarter Vermont scored its third strait goal, this one by Jeff Gordon. At 11:49 left in the quarter junior Jeff Kaylor (Beverly, Mass.) answered back with an unassisted goal to tie the game. Vermont's Dan Zwirko came back with a goal at the 7:08 mark, but BU tied it 32 seconds later when sophomore Rob Williams found the net from junior Sean Meluney (Cape Henlopen, Del.) to tie the game up again.
The forth quarter opened with an unassisted goal by Smith at the 13:52 mark to give the Bearcats the 7-6 advantage. With 53 seconds left in regulation Zwirko kept Vermont's hopes alive on his unassisted goal to send the game into sudden death overtime.
In the first overtime junior Kevin McKeown (Brewster, N.Y.) made three stunning saves to keep the Bearcats in the game, two of which came in the final 30 seconds of the the first overtime. In the second overtime Binghamton won the faceoff and had a pair of shots by Smith then by McNamara, which both missed before McNamara scored the game winner on an assist from DeCirce.
"McKeown was amazing, he made three spectacular saves in overtime which kept us in the game," head coach Ed Stephenson said. "We knew this game could have gone either way. This is what we will expect for league play."
McKeown made 12 saves while facing 28 shots, Vermont goalie Mike Gabel made 11 saves on 31 shots. Vermont had 34 ground balls, while the Bearcats had 32. The teams split the faceoffs, winning 10 each.
The Bearcats next head to Colgate for their final regular season non-conference matchup Tuesday at 7 p.m.
Sports Men: Baseball | Basketball | Cross Country | Golf | Lacrosse | Soccer | Swimming and Diving | Tennis | Track and Field | Wrestling |
Sports Women: Basketball | Cross Country | Lacrosse | Soccer | Softball | Swimming and Diving | Tennis | Track and Field | Volleyball |
No portion of this site may be reproduced or duplicated without the permission of Binghamton University.